<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04668976</url>
  </required_header>
  <id_info>
    <org_study_id>CRP19045</org_study_id>
    <nct_id>NCT04668976</nct_id>
  </id_info>
  <brief_title>A Study of the Use of the Medtronic Pump and Codman Catheter to Give Chemotherapy to Patients With Colorectal Carcinoma or Cholangiocarcinoma</brief_title>
  <official_title>A Pilot Protocol Evaluating Safety of the Medtronic Pump and Codman Catheter for the Delivery of Hepatic Arterial Infusion (HAI) Chemotherapy in Patients With Advanced Colorectal Carcinoma or Cholangiocarcinoma</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Benaroya Research Institute</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Virginia Mason Hospital/Medical Center</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>Benaroya Research Institute</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>Yes</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      This study is being done to answer the following question:&#xD;
&#xD;
      Is the combination of the Medtronic pump and the Codman catheter device a safe alternative to&#xD;
      the C3000 Codman pump for delivering chemotherapy directly into the liver of patients with&#xD;
      metastatic colorectal cancer or cholangiocarcinoma?&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Group 1 unresectable liver metastases from colorectal cancer&#xD;
&#xD;
      - Patients will receive either FOLFIRI, FOLFOX, Irinotecan or Irinotecan/oxaliplatin (anti-&#xD;
      EGFR agent may be added to any of the systemic treatments) on Days 1 and 15 of each cycle,&#xD;
      however initiation with systemic chemotherapy will not take place until 4 weeks post-surgery&#xD;
      for pump placement.&#xD;
&#xD;
      Group 2 resectable liver metastases from colorectal cancer - Patients will receive either&#xD;
      FOLFIRI, FOLFOX, Irinotecan or Irinotecan/oxaliplatin on Days 1 and 15 of each cycle, however&#xD;
      initiation with systemic chemotherapy will not take place until 4 weeks post-surgery for pump&#xD;
      placement.&#xD;
&#xD;
      Group 3 unresectable cholangiocarcinoma&#xD;
&#xD;
      - Patients will receive Gemcitabine (800 mg/m2 IV over 30 minutes) and Oxaliplatin (85 mg/ m2&#xD;
      IV over 120 minutes) or Gemcitabine (1000 mg/m2 IV over 30 minutes) alone on Days 1 and 15 of&#xD;
      each cycle, however initiation with systemic chemotherapy will not take place until 4 weeks&#xD;
      post-surgery for pump placement.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">November 25, 2020</start_date>
  <completion_date type="Anticipated">December 2024</completion_date>
  <primary_completion_date type="Anticipated">December 2023</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>N/A</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <intervention_model_description>Pilot non- randomized safety study</intervention_model_description>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Number of patients requiring stent replacements</measure>
    <time_frame>1 year</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Percent frequency liver toxicity</measure>
    <time_frame>1 year</time_frame>
    <description>Alkaline phosphatase percent toxicity, Serum bilirubin percent toxicity</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Overall survival</measure>
    <time_frame>1 year</time_frame>
    <description>Overall survival is defined as the time from treatment initiation till the day of death or last follow-up whichever occurs first.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Progression free survival</measure>
    <time_frame>1 year</time_frame>
    <description>Progression free survival is defined as the time from treatment initiation till the day of progression or death whichever occurs first. Patients that are alive without progression at the end of the study will be censored.</description>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Anticipated">100</enrollment>
  <condition>Colorectal Cancer</condition>
  <condition>Cholangiocarcinoma</condition>
  <arm_group>
    <arm_group_label>Pump Therapy</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>All patients will undergo surgery to have the Medtronic pump and Codman catheter placed appropriately before HAI therapy can begin.</description>
  </arm_group>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>Medtronic pump and Codman catheter</intervention_name>
    <description>All patients will undergo surgery to have the Medtronic pump and Codman catheter placed appropriately before HAI therapy can begin.</description>
    <arm_group_label>Pump Therapy</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Floxuridine (FUDR)</intervention_name>
    <description>Please see Detailed Description.</description>
    <arm_group_label>Pump Therapy</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Gemcitabine</intervention_name>
    <description>Please see Detailed Description.</description>
    <arm_group_label>Pump Therapy</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Oxaliplatin</intervention_name>
    <description>Please see Detailed Description.</description>
    <arm_group_label>Pump Therapy</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Irinotecan (CPT-11)</intervention_name>
    <description>Please see Detailed Description.</description>
    <arm_group_label>Pump Therapy</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Fluorouracil</intervention_name>
    <description>Please see Detailed Description.</description>
    <arm_group_label>Pump Therapy</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Anti-EGFR (Panitumumab or Cetuximab)</intervention_name>
    <description>Please see Detailed Description.</description>
    <arm_group_label>Pump Therapy</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          1. History of histologically confirmed colorectal adenocarcinoma metastatic to the liver&#xD;
             with no clinically or radiographically confirmed extrahepatic disease (or)&#xD;
             Histologically confirmed cholangiocarcinoma (Clinical or radiographic evidence of&#xD;
             metastatic disease that has been resected is allowed, provided there is no recurrence&#xD;
             in that area prior to protocol consent)&#xD;
&#xD;
          2. Confirmation of diagnosis must be performed at VMMC&#xD;
&#xD;
          3. Participant may have completely resected hepatic metastases without current evidence&#xD;
             of other metastatic disease&#xD;
&#xD;
          4. Lab values ≤14 days prior to registration:&#xD;
&#xD;
             ANC ≥ 1.0(9)/L Platelet count ≥ 75 (9)/L Creatinine ≤1.8 mg/dL AST 0 to 2x reference&#xD;
             value ALK PHOS 0 to &lt; 1.2 x reference value Tot Bili 0 to &lt; 1.2 x reference value&#xD;
&#xD;
          5. Prior chemotherapy is acceptable if last dose of oxaliplatin or irinotecan is given ≥3&#xD;
             weeks prior to planned first dosing on this protocol. 5-FU or 5-FU leucovorin may be&#xD;
             given ≥2 weeks prior to planned first dosing on this protocol. [Note: no chemotherapy&#xD;
             to be given after resection of liver lesions prior to treatment on this study]&#xD;
&#xD;
          6. Any investigation agent is acceptable if administered ≥3 months before planned first&#xD;
             dose on this protocol&#xD;
&#xD;
          7. ECOG &lt;=1&#xD;
&#xD;
          8. Participants ≥18 years of age&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          1. Prior radiation to the liver (prior radiation therapy to the pelvis is acceptable if&#xD;
             competed at least 4 weeks prior to the planned first dose of treatment on protocol)&#xD;
&#xD;
          2. Colorectal cancer that is BRAF mutant or defective in mismatch repair.&#xD;
&#xD;
          3. Active infection, ascites, hepatic encephalopathy&#xD;
&#xD;
          4. Female participants who are pregnant or lactating - or planning to become pregnant&#xD;
             within 6 months after the end of the treatment (female participants of child-bearing&#xD;
             potential must have negative pregnancy test ≤72 hours before treatment start)&#xD;
&#xD;
          5. If in the opinion of the treating investigator a participant has any serious medical&#xD;
             problems which may preclude receiving this type of treatment&#xD;
&#xD;
          6. Participants with current evidence of hepatitis A, B, C (i.e., active hepatitis)&#xD;
&#xD;
          7. Participants with history or known presence of primary CNS tumors, seizures not well-&#xD;
             controlled with standard medical therapy, or history of stroke will also be excluded&#xD;
&#xD;
          8. Serious or non-healing active wound, ulcer, or bone fracture&#xD;
&#xD;
          9. History of other malignancy, except:&#xD;
&#xD;
               1. Malignancy treated with curative intent and with no known active disease present&#xD;
                  for ≥3 years prior to registration and felt to be at low risk for recurrence by&#xD;
                  the treating physician&#xD;
&#xD;
               2. Adequately treated non-melanomatous skin cancer or lentigo malignant without&#xD;
                  evidence of disease&#xD;
&#xD;
               3. Adequately treated cervical carcinoma in situ without evidence of disease&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Hagen Kennecke, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Virginia mason medical Center</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Hagen Kennecke, MD</last_name>
    <phone>206-223-6193</phone>
    <email>Hagen.Kennecke@virginiamason.org</email>
  </overall_contact>
  <location>
    <facility>
      <name>Virginia mason medical Center</name>
      <address>
        <city>Seattle</city>
        <state>Washington</state>
        <zip>98101</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Hagen Kennecke, MD</last_name>
      <phone>206-223-6193</phone>
      <email>Hagen.Kennecke@virginiamason.org</email>
    </contact>
    <investigator>
      <last_name>Hagen Kennecke, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>December 2020</verification_date>
  <study_first_submitted>December 6, 2020</study_first_submitted>
  <study_first_submitted_qc>December 10, 2020</study_first_submitted_qc>
  <study_first_posted type="Actual">December 16, 2020</study_first_posted>
  <last_update_submitted>December 17, 2020</last_update_submitted>
  <last_update_submitted_qc>December 17, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">December 21, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Medtronic Pump</keyword>
  <keyword>Codman Catheter</keyword>
  <keyword>Hepatic Arterial Infusion (HAI)</keyword>
  <keyword>Floxuridine (FUDR)</keyword>
  <keyword>Gemcitabine</keyword>
  <keyword>Oxaliplatin</keyword>
  <keyword>Irinotecan (CPT-11)</keyword>
  <keyword>Fluorouracil</keyword>
  <keyword>Leucovorin Calcium (Folinic Acid)</keyword>
  <keyword>Dexamethasone</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Colorectal Neoplasms</mesh_term>
    <mesh_term>Cholangiocarcinoma</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Gemcitabine</mesh_term>
    <mesh_term>Fluorouracil</mesh_term>
    <mesh_term>Floxuridine</mesh_term>
    <mesh_term>Oxaliplatin</mesh_term>
    <mesh_term>Irinotecan</mesh_term>
    <mesh_term>Cetuximab</mesh_term>
    <mesh_term>Panitumumab</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

